Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.
Hoekstra CJ, Stroobants SG, Hoekstra OS, Vansteenkiste J, Biesma B, Schramel FJ, van Zandwijk N, van Tinteren H, Smit EF. Hoekstra CJ, et al. Among authors: van tinteren h, van zandwijk n. Lung Cancer. 2003 Feb;39(2):151-7. doi: 10.1016/s0169-5002(02)00446-4. Lung Cancer. 2003. PMID: 12581567
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.
van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, van Velthoven PC, Comans EF, Diepenhorst FW, Verboom P, van Mourik JC, Postmus PE, Boers M, Teule GJ. van Tinteren H, et al. Among authors: van den bergh jh, van velthoven pc, van mourik jc. Lancet. 2002 Apr 20;359(9315):1388-93. doi: 10.1016/s0140-6736(02)08352-6. Lancet. 2002. PMID: 11978336 Clinical Trial.
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, van Zandwijk N, Lammertsma AA, Hoekstra OS. Hoekstra CJ, et al. Among authors: van tinteren h, van zandwijk n. J Clin Oncol. 2005 Nov 20;23(33):8362-70. doi: 10.1200/JCO.2005.01.1189. J Clin Oncol. 2005. PMID: 16293866 Clinical Trial.
Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study.
Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, Comans EF, Verboom P, Uyl-de Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ, Groen HJ; POORT Study Group. Herder GJ, et al. Among authors: van tinteren h. J Clin Oncol. 2006 Apr 20;24(12):1800-6. doi: 10.1200/JCO.2005.02.4695. Epub 2006 Mar 27. J Clin Oncol. 2006. PMID: 16567772 Clinical Trial.
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
Verboom P, van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, van Velthoven PC, Comans EF, Diepenhorst FW, van Mourik JC, Postmus PE, Boers M, Grijseels EW, Teule GJ, Uyl-de Groot CA; PLUS study group. Verboom P, et al. Among authors: van den bergh jh, van velthoven pc, van mourik jc, van tinteren h. Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1444-9. doi: 10.1007/s00259-003-1199-9. Epub 2003 May 29. Eur J Nucl Med Mol Imaging. 2003. PMID: 14579081 Clinical Trial.
327 results